CJC-1295 / Ipamorelin / GHRP-2 Blend
A triple-peptide research blend combining CJC-1295 (GHRH analogue), Ipamorelin, and GHRP-2 (two mechanistically distinct ghrelin receptor agonists), designed to maximize growth hormone release through concurrent triple-pathway activation of pituitary somatotrophs.
CJC-1295 / Ipamorelin / GHRP-2 is a triple-peptide blend that represents the most comprehensive secretagogue approach to growth hormone axis activation studied in peptide research. By combining a GHRH receptor agonist (CJC-1295) with two pharmacologically distinct ghrelin receptor agonists (Ipamorelin and GHRP-2), the blend activates the GH axis through three overlapping but non-identical signaling inputs.
Overview
This triple blend builds on the well-established synergy between GHRH and ghrelin-pathway agonists by incorporating two GHS-R1a ligands with distinct pharmacological fingerprints. CJC-1295 (Mod GRF 1-29) provides the GHRH-receptor input, driving cAMP/PKA-mediated GH gene transcription and somatotroph priming. Ipamorelin and GHRP-2 both activate GHS-R1a but differ substantially in their downstream consequences: Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation (Raun et al., 1998), while GHRP-2 generates robust GH output alongside measurable increases in ACTH, cortisol, prolactin, and appetite-stimulating signals.
The combination of two GHS-R1a agonists is hypothesized to produce more complete receptor activation through potential differences in receptor binding kinetics, biased agonism profiles, and secondary target engagement. GHRP-2 additionally activates hypothalamic NPY/AgRP neurons involved in appetite regulation and has demonstrated immunomodulatory properties in research models.
Mechanism of Action
The triple-pathway amplification model operates through three converging inputs:
GHRH Pathway (CJC-1295): Activation of the GHRH receptor on somatotrophs stimulates adenylyl cyclase via Gs-alpha coupling, increasing cAMP and activating PKA. This drives GH gene transcription, de novo GH protein synthesis, and priming of secretory vesicles for calcium-dependent release. GHRH also promotes somatotroph proliferation over longer exposure periods.
Selective Ghrelin Pathway (Ipamorelin): Ipamorelin binds GHS-R1a and activates Gq/11-coupled PLC signaling, generating IP3 and DAG. The resulting intracellular calcium mobilization triggers rapid exocytosis of pre-formed GH vesicles. Ipamorelin's key distinguishing feature is its failure to significantly stimulate ACTH or cortisol release at GH-effective doses, suggesting preferential activation of specific downstream signaling branches.
Broad Ghrelin Pathway (GHRP-2): GHRP-2 also activates GHS-R1a but engages a broader signaling response. Beyond somatotroph GH release, GHRP-2 activates hypothalamic circuits that suppress somatostatin release and stimulate endogenous GHRH secretion, creating a feed-forward loop. Laferrere et al. (2006) demonstrated that GHRP-2 stimulates appetite through central mechanisms, indicating engagement of arcuate nucleus NPY pathways. This broader activation profile may contribute to metabolic effects beyond isolated GH release.
Triple Convergence: The combination produces GH output through at least three amplification mechanisms: (1) GHRH/ghrelin receptor synergy at the somatotroph level, as established by Bowers (1990); (2) GHRP-2-mediated suppression of somatostatin tone, removing the hypothalamic brake on GH release; and (3) potential complementary receptor occupancy dynamics from two structurally distinct GHS-R1a ligands.
Reconstitution Calculator
CJC-1295 / Ipamorelin / GHRP-2 Blend
**CJC-1295 / Ipamorelin / GHRP-2** is a triple-peptide blend that represents the
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
GHRH-GHS Synergy Foundations
The principle that GHRH and growth hormone secretagogues produce synergistic rather than additive GH release was established in landmark studies by Bowers and colleagues. Bowers et al. (1990) demonstrated in human subjects that co-administration of GHRH with GH-releasing peptides produced GH peaks substantially exceeding predictions from simple additivity, establishing the pharmacological basis for GHRH/GHS blend formulations.
CJC-1295 Clinical Pharmacology
Teichman et al. (2006) characterized the pharmacokinetics and pharmacodynamics of CJC-1295 in healthy adults, demonstrating dose-dependent and sustained increases in GH, IGF-1, and IGFBP-3 levels. This study established the clinical viability of modified GHRH analogues and provided the pharmacological foundation for using CJC-1295 as the GHRH component in multi-peptide blends.
Ipamorelin Selectivity Profile
Raun et al. (1998) first characterized Ipamorelin as the most selective growth hormone secretagogue identified at the time. In swine models, Ipamorelin produced dose-dependent GH release comparable to GHRP-6 but without significant elevation of ACTH, cortisol, or prolactin. This selectivity profile makes Ipamorelin a valuable complement to the broader-acting GHRP-2 in a triple blend, potentially moderating the overall off-target hormonal impact.
GHRP-2 Appetite and Metabolic Effects
Laferrere et al. (2006) investigated the appetite-stimulating properties of GHRP-2 in lean and obese human subjects, demonstrating significant increases in food intake following intravenous administration. The appetite effect is mediated through activation of hypothalamic feeding circuits, particularly NPY/AgRP neurons in the arcuate nucleus, representing a pharmacological dimension absent from Ipamorelin.
Growth Hormone Axis Regulation
Ionescu and Bhatt (2006) reviewed the physiology of the GH-IGF axis and the pharmacological strategies for modulating GH secretion, providing mechanistic context for multi-secretagogue approaches. Their analysis describes how concurrent GHRH receptor activation and somatostatin suppression (achieved through ghrelin-pathway agonists) can produce sustained enhancement of GH pulsatility while maintaining physiological feedback regulation.
Safety Profile
The safety profile of this triple blend reflects the combined characteristics of its individual components. CJC-1295 (no DAC) and Ipamorelin have favorable safety profiles individually, with Ipamorelin notable for minimal cortisol and prolactin elevation (Raun et al., 1998). GHRP-2 introduces additional considerations including potential cortisol and prolactin elevation, appetite stimulation, and effects on glucose metabolism. Common observations across GH secretagogue research include transient injection-site reactions, flushing, and water retention. As with all GH-elevating approaches, theoretical concerns include effects on insulin sensitivity and promotion of growth in pre-existing neoplasms. The interaction profile of three concurrent secretagogues has not been extensively characterized in controlled clinical trials.
Pharmacokinetic Profile
CJC-1295 / Ipamorelin / GHRP-2 Blend — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Route
- Subcutaneous injection
Research Protocols
intravenous Injection
Administered via intravenous injection.
subcutaneous Injection
Administered via subcutaneous injection.
Interactions
Peptide Interactions
gov/2153518/); (2) GHRP-2-mediated suppression of somatostatin tone, removing the hypothalamic brake on GH release; and (3) potential complementary receptor occupancy dynamics from two structurally distinct GHS-R1a ligands.
What to Expect
What to Expect
Rapid onset expected; half-life of CJC-1295 (no DAC): ~30 min; Ipamorelin: ~2 hr; GHRP-2: ~1-2 hr indicates fast-acting pharmacokinetics
Due to short half-life (CJC-1295 (no DAC): ~30 min; Ipamorelin: ~2 hr; GHRP-2: ~1-2 hr), effects are expected per-dose; consistent daily...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
- Multiple peer-reviewed studies available
Caution
- Injection site reactions reported
Frequently Asked Questions
References (5)
- [1]Bowers CY et al On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone Endocrinology (1990)
- [2]Teichman SL et al Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults J Clin Endocrinol Metab (2006)
- [3]
- [5]Ionescu M, Bhatt DL Growth hormone-releasing hormone (GHRH) and the GH-IGF axis Rev Endocr Metab Disord (2006)
- [4]Laferrere B et al Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men J Clin Endocrinol Metab (2006)
CJC-1295 (Mod GRF 1-29)
CJC-1295 without DAC (Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone with four amino acid substitutions that enhance metabolic stability. It promotes pulsatile GH release with a short half-life of approximately 30 minutes.
CNTF
Ciliary Neurotrophic Factor (CNTF) is a member of the IL-6 cytokine family that signals through the CNTFRα/LIFRβ/gp130 tripartite receptor complex to activate JAK/STAT3 signaling, with research applications in ALS, retinal degeneration, and obesity.